Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21757517 | 0.92 | OPRL1 (0.49) | OPRL1CHRNB2CHRNA4CYP11B2HTR2C | |
| SCHEMBL21757505 | 0.90 | OPRL1 (0.48) | OPRL1CHRNB2CHRNA4CYP11B2 | |
| SCHEMBL21757521 | 0.90 | OPRL1 (0.48) | OPRL1CHRNB2CHRNA4CYP11B2 | |
| Hydrochloric Acid SCHEMBL28413629 | 0.89 | OPRL1 (0.48) | OPRL1CHRNB2CHRNA4CYP17A1CYP11B1 | |
| SCHEMBL23974564 | 0.83 | OPRL1 (0.60) | OPRL1CHRNB2CHRNA4IDO1 | |
| SCHEMBL16132536 | 0.83 | OPRL1 (0.57) | OPRL1CYP17A1HTR2CIDO1 | |
| SCHEMBL29889741 | 0.80 | HTR2C (0.46) | OPRL1HTR2C | |
| SCHEMBL13347725 | 0.76 | OPRL1 (0.52) | OPRL1CYP17A1IDO1 | |
| SCHEMBL14614990 | 0.75 | CYP11B1 (0.46) | OPRL1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL14615235 | 0.75 | CYP11B1 (0.46) | OPRL1CHRNB2CHRNA4CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2012084678-A1 | NOVEL IMIDAZOLES USEFUL AS PLANT FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | OPRL1 4725/4885CHRNB2 4687/4885CHRNA4 4864/4885 |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | OPRL1 3907/4885CHRNB2 2465/4885CHRNA4 2237/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | OPRL1 4692/4885CHRNB2 4744/4885CHRNA4 4869/4885 |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | OPRL1 3907/4885CHRNB2 2465/4885CHRNA4 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.